These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
194 related articles for article (PubMed ID: 10914103)
1. Newborn screening for cystic fibrosis in Victoria: 10 years' experience (1989-1998). Massie RJ; Olsen M; Glazner J; Robertson CF; Francis I Med J Aust; 2000 Jun; 172(12):584-7. PubMed ID: 10914103 [TBL] [Abstract][Full Text] [Related]
2. Lessons learned from 20 years of newborn screening for cystic fibrosis. Massie RJ; Curnow L; Glazner J; Armstrong DS; Francis I Med J Aust; 2012 Jan; 196(1):67-70. PubMed ID: 22256939 [TBL] [Abstract][Full Text] [Related]
5. Population-based newborn screening for genetic disorders when multiple mutation DNA testing is incorporated: a cystic fibrosis newborn screening model demonstrating increased sensitivity but more carrier detections. Comeau AM; Parad RB; Dorkin HL; Dovey M; Gerstle R; Haver K; Lapey A; O'Sullivan BP; Waltz DA; Zwerdling RG; Eaton RB Pediatrics; 2004 Jun; 113(6):1573-81. PubMed ID: 15173476 [TBL] [Abstract][Full Text] [Related]
6. Application of DNA analysis in a population-screening program for neonatal diagnosis of cystic fibrosis (CF): comparison of screening protocols. Gregg RG; Wilfond BS; Farrell PM; Laxova A; Hassemer D; Mischler EH Am J Hum Genet; 1993 Mar; 52(3):616-26. PubMed ID: 7680526 [TBL] [Abstract][Full Text] [Related]
7. Neonatal screening for cystic fibrosis using immunoreactive trypsinogen and direct gene analysis: four years' experience. Ranieri E; Lewis BD; Gerace RL; Ryall RG; Morris CP; Nelson PV; Carey WF; Robertson EF BMJ; 1994 Jun; 308(6942):1469-72. PubMed ID: 8019280 [TBL] [Abstract][Full Text] [Related]
8. Markedly elevated neonatal immunoreactive trypsinogen levels in the absence of cystic fibrosis gene mutations is not an indication for further testing. Massie J; Curnow L; Tzanakos N; Francis I; Robertson CF Arch Dis Child; 2006 Mar; 91(3):222-5. PubMed ID: 16243854 [TBL] [Abstract][Full Text] [Related]
9. Initial evaluation of a biochemical cystic fibrosis newborn screening by sequential analysis of immunoreactive trypsinogen and pancreatitis-associated protein (IRT/PAP) as a strategy that does not involve DNA testing in a Northern European population. Sommerburg O; Lindner M; Muckenthaler M; Kohlmueller D; Leible S; Feneberg R; Kulozik AE; Mall MA; Hoffmann GF J Inherit Metab Dis; 2010 Oct; 33(Suppl 2):S263-71. PubMed ID: 20714932 [TBL] [Abstract][Full Text] [Related]
10. Newborn screening for cystic fibrosis in Wisconsin: nine-year experience with routine trypsinogen/DNA testing. Rock MJ; Hoffman G; Laessig RH; Kopish GJ; Litsheim TJ; Farrell PM J Pediatr; 2005 Sep; 147(3 Suppl):S73-7. PubMed ID: 16202788 [TBL] [Abstract][Full Text] [Related]
11. The impact of newborn screening on cystic fibrosis testing in Victoria, Australia. Balnaves ME; Bonacquisto L; Francis I; Glazner J; Forrest S J Med Genet; 1995 Jul; 32(7):537-42. PubMed ID: 7562966 [TBL] [Abstract][Full Text] [Related]
12. Neonatal screening for cystic fibrosis: a comparison of two strategies for case detection in 1.2 million babies. Wilcken B; Wiley V; Sherry G; Bayliss U J Pediatr; 1995 Dec; 127(6):965-70. PubMed ID: 8523199 [TBL] [Abstract][Full Text] [Related]
14. Negative sweat test in hypertrypsinaemic infants with cystic fibrosis carrying rare CFTR mutations. Padoan R; Bassotti A; Seia M; Corbetta C Eur J Pediatr; 2002 Apr; 161(4):212-5. PubMed ID: 12014388 [TBL] [Abstract][Full Text] [Related]
15. Screening for cystic fibrosis in newborn infants: results of a pilot programme based on a two tier protocol (IRT/DNA/IRT) in the Italian population. Corbetta C; Seia M; Bassotti A; Ambrosioni A; Giunta A; Padoan R J Med Screen; 2002; 9(2):60-3. PubMed ID: 12133923 [TBL] [Abstract][Full Text] [Related]